[HTML][HTML] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi, NA Damle… - PLoS …, 2021 - journals.plos.org
Objective Investigators have extensively explored the short-term safety and efficacy data on
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
[HTML][HTML] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi, NA Damle… - PLoS ONE, 2021 - ncbi.nlm.nih.gov
Objective Investigators have extensively explored the short-term safety and efficacy data on
177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
MP Yadav, S Ballal, RK Sahoo, M Tripathi, NA Damle… - Plos one, 2021 - europepmc.org
Objective Investigators have extensively explored the short-term safety and efficacy data on
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
MP Yadav, S Ballal, RK Sahoo, M Tripathi… - PLoS …, 2021 - search.ebscohost.com
Objective: Investigators have extensively explored the short-term safety and efficacy data
on< sup> 177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However …
on< sup> 177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However …
Long-term outcome of. sup. 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
MP Yadav, S Ballal, RK Sahoo, M Tripathi, NA Damle… - PLoS ONE, 2021 - go.gale.com
Objective Investigators have extensively explored the short-term safety and efficacy data on.
sup. 177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce …
sup. 177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce …
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi… - PloS …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective Investigators have extensively explored the short-term safety and efficacy data on
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
[PDF][PDF] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi… - PLoS …, 2021 - pdfs.semanticscholar.org
Objective Investigators have extensively explored the short-term safety and efficacy data on
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
[引用][C] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi… - PLoS …, 2021 - ui.adsabs.harvard.edu
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic
castration-resistant prostate cancer patients - NASA/ADS Now on home page ads icon ads …
castration-resistant prostate cancer patients - NASA/ADS Now on home page ads icon ads …
[PDF][PDF] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, RK Sahoo, M Tripathi… - PLoS ONE, 2021 - scholar.archive.org
Objective Investigators have extensively explored the short-term safety and efficacy data on
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
M Yadav, S Ballal, C Bal, M Tripathi, N Damle… - 2021 - Soc Nuclear Med
1307 Objectives: Investigators have extensively explored the short-term safety and efficacy
data on 177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce …
data on 177 Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce …